Literature DB >> 16128894

Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time.

C S Philipp1, C H Miller, A Faiz, A Dilley, L A Michaels, C Ayers, G Bachmann, N Dowling, P Saidi.   

Abstract

Menorrhagia is a very common clinical problem among women of reproductive age and recent studies have suggested that underlying bleeding disorders, particularly von Willebrand's deficiency and platelet function defects, are prevalent in women presenting with menorrhagia. The objective of this study was to determine the utility of the platelet function analyser (PFA-100) and bleeding time (BT) as initial screening tests for underlying bleeding disorders in women with menorrhagia. In this study, 81 women with a physician diagnosis of menorrhagia underwent PFA-100 testing, BT and comprehensive haemostatic testing. The effectiveness of the PFA-100 and BT as screening tools in women with menorrhagia was assessed using results of haemostatic testing for von Willebrand's disease (VWD) and platelet dysfunction. In women presenting with menorrhagia, the PFA-100 had a sensitivity 80%, specificity 89%, positive predictive value (PPV) 33%, negative predictive value (NPV) 98% and efficiency 88% for VWD. For platelet aggregation defects, the PFA-100 closure time had a sensitivity 23%, specificity 92%, PPV of 75%, NPV of 52% and efficiency 55%. The data suggest that the PFA-100 may be useful in stratifying women with menorrhagia for further von Willebrand testing; however, neither the PFA-100 nor the BT tests are effective for purposes of classifying women for standard platelet aggregometry testing in women presenting with menorrhagia.

Entities:  

Mesh:

Year:  2005        PMID: 16128894     DOI: 10.1111/j.1365-2516.2005.01129.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  6 in total

1.  The Prevalence of von Willebrand Disease and Significance of in Vitro Bleeding Time (PFA-100) in von Willebrand Disease Screening in the İzmir Region.

Authors:  Fatih Sap; Tülay Kavaklı; Kaan Kavaklı; Ceyhun Dizdarer
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

Review 2.  Platelet function tests: a comparative review.

Authors:  Rita Paniccia; Raffaella Priora; Agatina Alessandrello Liotta; Rosanna Abbate
Journal:  Vasc Health Risk Manag       Date:  2015-02-18

Review 3.  Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications.

Authors:  Katalin Koltai; Gabor Kesmarky; Gergely Feher; Antal Tibold; Kalman Toth
Journal:  Int J Mol Sci       Date:  2017-08-18       Impact factor: 5.923

4.  Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding.

Authors:  Anne D Rocheleau; Ayesha Khader; Anh T P Ngo; Colin Boehnlein; Cara McDavitt; Susan Lattimore; Michael Recht; Owen J T McCarty; Kristina M Haley
Journal:  Pediatr Res       Date:  2018-01-03       Impact factor: 3.756

5.  Harmonizing platelet function analyzer testing and reporting in a large laboratory network.

Authors:  Emmanuel J Favaloro; Soma Mohammed; Ronny Vong; Kent Chapman; Geoffrey Kershaw; Sarah Just; Lynne Connelly; Michael Ryan; Diane Zebeljan; Timothy Brighton; Leonardo Pasalic
Journal:  Int J Lab Hematol       Date:  2022-06-26       Impact factor: 3.450

6.  Clinical and laboratory characteristics of adolescents with platelet function disorders and heavy menstrual bleeding.

Authors:  Lawrence S Amesse; Teresa Pfaff-Amesse; William T Gunning; Nancy Duffy; James A French
Journal:  Exp Hematol Oncol       Date:  2013-01-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.